(Q47753755)

5 February 2018

title

Expressions of ER, PR, HER-2, COX-2, and VEGF in primary and relapsed/metastatic breast cancers (English)

1 reference

5 February 2018

author name string

Li Sun

1

1 reference

5 February 2018

Da-hai Yu

2

1 reference

5 February 2018

San-Yuan Sun

3

1 reference

5 February 2018

Shi-Chao Zhuo

4

1 reference

5 February 2018

Su-sheng Cao

5

1 reference

5 February 2018

Ling Wei

6

1 reference

5 February 2018

publication date

1 April 2014

1 reference

5 February 2018

Cell Biochemistry and Biophysics

published in

1 reference

5 February 2018

volume

68

1 reference

5 February 2018

issue

3

1 reference

5 February 2018

page(s)

511-516

1 reference

5 February 2018

Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9729-Y

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9729-Y

A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9729-Y

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9729-Y

Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9729-Y

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9729-Y

COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9729-Y

Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9729-Y

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-013-9729-Y

10.1007/S12013-013-9729-Y

21 January 2018

Identifiers

DOI

1 reference

5 February 2018

1 reference

5 February 2018